An investor gestures as he monitors a screen displaying stock information in Riyadh, Saudi Arabia, November 6, 2017. REUTERS/Faisal Al Nasser
Your feedback is important to us!
We invite all our readers to share with us their views and comments about this article.
Disclaimer: Comments submitted by third parties on this site are the sole responsibility of the individual(s) whose content is submitted. The Daily Star accepts no responsibility for the content of comment(s), including, without limitation, any error, omission or inaccuracy therein. Please note that your email address will NOT appear on the site.
Alert: If you are facing problems with posting comments, please note that you must verify your email with Disqus prior to posting a comment. follow this link to make sure your account meets the requirements. (http://bit.ly/vDisqus)
Saudi stocks are becoming pricier as the country heads for inclusion in major emerging-market benchmarks.The earnings outlook is appealing to some too: Mouwasat's gross profit margin remains in the high-40 percent range, far outpacing the figures for Saudi competitors, said Asim Bukhtiar, an analyst at Saudi Fransi Capital in Riyadh.Morgan Stanley expects Mouwasat's free cash flow yield to rise 5.3 percent in 2020 while Arqaam Capital believes the company has the advantage of being present across the country and views it as a "core buy".EFG-Hermes considers Mouwasat to be the "best-in-class" health care provider in Saudi Arabia and says that its stock price is 11 percent below its five-year average forward price-to-earnings ratio.
FOLLOW THIS ARTICLE